論文

SMCラボラトリーズは、製薬企業や研究機関のご要望に沿った試験をデザインするコンサルティング型の
CROとして世界的に⾼い評価をいただいています。
特にMASH/NASHの研究分野では、当社独自のSTAM™マウスを用いた薬効評価試験サービスを提供しており、
STAM™マウスを用いた研究成果は雑誌や学会などで多く公表されております。

Publications

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

No.49

2019

International Journal of Molecular Medicine,

“The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice.” (Int J Mol Med, 44(6):2256-2264, 2019)
VIEW ARTICLE bug

No.48

2019

Science Translational Medicine,

“Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis” (Sci Transl Med., 11(520), 2019)
VIEW ARTICLE bug

No.47

2019

Cells,

“Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis” (Cells, 8;8(11), 2019)
VIEW ARTICLE bug

No.46

2019

International Journal of Molecular Sciences,

“The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma”(Int. J. Mol. Sci. , 20(20), 5237, 2019)
VIEW ARTICLE bug

No.45

2019

Toxicological Sciences,

“Gene Expression and DNA Methylation Alterations in the Glycine N-Methyltransferase Gene in Diet-Induced Nonalcoholic Fatty Liver Disease-Associated Carcinogenesis.”(Toxicol Sci., 170(2):273-282, 2019)
VIEW ARTICLE bug

No.44

2019

Biochemistry,

“A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease” (Biochemistry, 58(37):3911-3917, 2019)
VIEW ARTICLE bug

No.43

2019

Hepatology Communications,

“Tropifexor‐Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents“ (Hepatol Commun., 3(8): 1085–1097, 2019)
VIEW ARTICLE bug

No.42

2019

International Journal of Gastroenterology,

"Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis" (International Journal of Gastroenterology, DOI: 10.11648/j.ijg.20190301.12, 2019)
VIEW ARTICLE bug

No.41

2019

Experimental Animals,

"Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM™ mice" (Exp Anim., DOI: 10.1538/expanim.18-0152, 2019)
VIEW ARTICLE bug

No.40

2019

Frontiers in Genetics,

"Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis" (Front Genet., May 29;10:486, 2019)
VIEW ARTICLE bug

No.39

2019

Journal of Cellular and Molecular Medicine,

"The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis" (J Cell Mol Med., 23:1759-1770, 2019)
VIEW ARTICLE bug

No.38

2019

Scientific Reports,

"Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan" (Sci Rep., Mar 8;9(1):4003, 2019)
VIEW ARTICLE bug